國家衛生研究院 NHRI:Item 3990099045/12456

NHRI > National Institute of Infectious Diseases and Vaccinology > Shu-Chen Kuo > Periodical Articles > Item 3990099045/12456

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12456

Title:	Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016
Authors:	Kuo, SC;Liu, CE;Lu, PL;Chen, YS;Lu, MC;Ko, WC;Hsueh, PR;Chuang, YC;Wang, FD;the SMART Asia-Pacific Group
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	This study aimed to investigate the susceptibility of respiratory Gram-negative bacteria to ceftolozane/tazobactam and other antibiotics in the Asia-Pacific region during 2015-2016. MICs were determined using the CLSI standard broth microdilution method and interpreted accordingly. Pseudomonas aeruginosa (1574 isolates), Klebsiella pneumoniae (1226), Acinetobacter baumannii (627) and Escherichia coli (476) accounted for 73.1% of 5342 Gram-negative respiratory pathogens. The susceptibility to ceftolozane/tazobactam of individual Enterobacteriaceae was >80%, except Enterobacter cloacae (76.6%). Ceftolozane/tazobactam inhibited 81.9% of K. pneumoniae and 91.9% of E. coli, with respective MIC50/MIC90 values of 0.5/>32 and 0.25/2 mg/L. For carbapenem-susceptible, ESBL-producing K. pneumoniae and E. coli, susceptibility was 65.5% and 93.3% and respective MIC50/MIC90 values were 2/>32 and 0.5/2 mg/L. BlaCTX-M-1 group was most prevalent in selected ESBL-producing K. pneumoniae (40 of 54) and E. coli (15 of 22) isolates, with ceftolozane/tazobactam susceptibility rates of 50% and 80%, respectively. BlaSHV-ESBL was the second most prevalent, and ceftolozane/tazobactam inhibited 20% of 20 K. pneumoniae isolates with blaSHV-ESBL. The only effective antibiotics for carbapenem-non-susceptible K. pneumoniae (111 isolates) and E. coli (24 isolates) were amikacin and colistin. Ceftolozane/tazobactam was effective against almost all P. aeruginosa and carbapenem-non-susceptible strains (333 isolates), with susceptibility of 92.3% and 72.8%, respectively; the respective MIC50/MIC90 values were 1/4 and 2/>32 mg/L. The high susceptibility of ceftolozane/tazobactam remained in different age groups, patient locations, recovery times and countries, except Vietnam. In conclusion, ceftolozane/tazobactam was effective against most respiratory Gram-negative pathogens in the Asia-Pacific region. However, the emergence of carbapenem resistance mandates ongoing surveillance.
Date:	2020-03
Relation:	International Journal of Antimicrobial Agents. 2020 Mar;55(3):Article number 105883.
Link to:	http://dx.doi.org/10.1016/j.ijantimicag.2020.105883
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0924-8579&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000518855500001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85078496364
Appears in Collections:	[Shu-Chen Kuo] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB31923574.pdf		796Kb	Adobe PDF	313	View/Open

Loading...